Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Other Non-Current Liabilities (2022 - 2025)

Serina Therapeutics' Other Non-Current Liabilities history spans 3 years, with the latest figure at $3.5 million for Q2 2025.

  • For Q2 2025, Other Non-Current Liabilities fell 73.54% year-over-year to $3.5 million; the TTM value through Jun 2025 reached $3.5 million, down 73.54%, while the annual FY2024 figure was $3.6 million, N/A changed from the prior year.
  • Other Non-Current Liabilities for Q2 2025 was $3.5 million at Serina Therapeutics, up from $2.6 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $24.1 million in Q1 2024 and bottomed at $180000.0 in Q4 2022.
  • The 3-year median for Other Non-Current Liabilities is $3.6 million (2024), against an average of $7.0 million.
  • The largest YoY upside for Other Non-Current Liabilities was 73.54% in 2025 against a maximum downside of 89.23% in 2025.
  • A 3-year view of Other Non-Current Liabilities shows it stood at $180000.0 in 2022, then soared by 1890.0% to $3.6 million in 2024, then fell by 0.92% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Other Non-Current Liabilities are $3.5 million (Q2 2025), $2.6 million (Q1 2025), and $3.6 million (Q4 2024).